BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Myelodysplastic syndromes clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for myelodysplastic syndromes: 175 (113 sponsors; 22 newly posted in the last 180 days, 10 stopped in the last 180 days; 13 new-entrant sponsors). Momentum score 7.7, rank 83 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 54, Phase 2 61, Phase 3 31, Phase 4 2, N/A 27.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Bristol-Myers Squibb BMY | 8 | NA 4, P3 3, P4 1 | 1 | 0 |
| Wuhan Createrna Science and Technology Co., Ltd | 4 | P3 3, P2 1 | 0 | 1 |
| Hoffmann-La Roche | 3 | P3 3 | 0 | 1 |
| Novartis Pharmaceuticals NVS | 11 | NA 5, P3 2, P1 2, P2 2 | 0 | 2 |
| Alexion Pharmaceuticals, Inc. | 5 | NA 3, P3 2 | 0 | 0 |
| Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 5 | P3 2, P1 2, NA 1 | 4 | 0 |
| Regeneron Pharmaceuticals REGN | 4 | P3 2, P1 1, P2 1 | 1 | 0 |
| Takeda TAK | 4 | P3 2, P2 2 | 0 | 0 |
| Nanjing Chia-tai Tianqing Pharmaceutical | 3 | P2 1, P3 2 | 0 | 0 |
| Celgene | 2 | P3 2 | 0 | 0 |
| Orca Biosystems, Inc. | 4 | P3 1, P2 1, P1 2 | 0 | 0 |
| Taiho Oncology, Inc. | 4 | P3 1, P2 1, P1 2 | 0 | 2 |
| Geron Corporation GERN | 2 | P3 1, P4 1 | 1 | 0 |
| AbbVie ABBV | 1 | P3 1 | 0 | 0 |
| Ascentage Pharma Group Inc. AAPG | 1 | P3 1 | 0 | 0 |
| Bisirna Therapeutics (Suzhou) Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| Kyntra Bio KYNB new entrant | 1 | P3 1 | 1 | 0 |
| Otsuka Australia Pharmaceutical Pty Ltd | 1 | P3 1 | 0 | 0 |
| Bellicum Pharmaceuticals | 4 | P1 2, P2 2 | 0 | 0 |
| AstraZeneca AZN | 3 | P2 1, NA 2 | 0 | 0 |
| NovelMed Therapeutics | 3 | P2 3 | 0 | 0 |
| Ossium Health, Inc. | 3 | NA 2, P2 1 | 1 | 0 |
| Akeso | 2 | P2 2 | 0 | 0 |
| ARCE Therapeutics, Inc. | 2 | P2 1, NA 1 | 0 | 0 |
| Faron Pharmaceuticals Ltd | 2 | P2 2 | 1 | 1 |
New-entrant sponsors: Bisirna Therapeutics (Suzhou) Co., Ltd., Kyntra Bio.
Recently stopped trials
- NCT05741346 BioCryst Pharmaceuticals - terminated: Sponsor decision Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria
- NCT05116774 BioCryst Pharmaceuticals - terminated: Sponsor decision BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 In
- NCT05116787 BioCryst Pharmaceuticals - terminated: Sponsor decision BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement In
- NCT06419634 Bristol-Myers Squibb - terminated: Inability to meet protocol objectives Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Par
- NCT04021368 Ryvu Therapeutics SA - terminated: RPD2 has been identified RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
- NCT06268574 Ryvu Therapeutics SA - terminated: Sponsor decision Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
- NCT05568225 Forma Therapeutics, Inc. - terminated: Futility assessment concluded low likelihood of the trial showing meaningful patient benefit. A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
- NCT07036718 Novartis Pharmaceuticals - terminated: Sponsor decision NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice
- NCT05086315 Sanofi - terminated: Early discontinuation based on strategic sponsor decision not driven by any safety concerns. First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractor
- NCT07681440 Bristol-Myers Squibb - terminated: Insufficient enrollment A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Kind Pharmaceuticals LLC | NCT06304103 A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome | Myelodysplastic Syndromes | recruiting | 63 |
| 2026-12 est. | P2 | Ryvu Therapeutics SA | NCT06987058 RVU120 Rollover Study | Advanced Solid Tumors; Acute Myeloid Leukaemia (AML); High-risk Myelodysplastic Syndrome | enrolling by invitation | 14 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P1/P2 | Aptose Biosciences Inc. | NCT03850574 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute | Leukemia, Myeloid, Acute; Refractory AML; Relapsed Adult AML; Myelodysplastic Syndrome With Excess B | recruiting | 240 |
| 2026-09-08 | P1/P2 | BlueSphere Bio, Inc | NCT06704152 BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | AML, Adult Recurrent; ALL, Recurrent, Adult; MDS | terminated | 2 |
| 2026-08 est. | P1/P2 | AB Science | NCT05211570 AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse; Myelodysplastic Syndrome Acut | recruiting | 78 |
| 2026-07-14 | P1/P2 | Ossium Health, Inc. | NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malign | Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; A | active not recruiting | 12 |
| 2026-06 est. | P1/P2 | Advanced BioDesign | NCT05601726 First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AM | Acute Myeloid Leukemia, Adult; Myelodysplastic Syndromes | recruiting | 36 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "myelodysplastic syndromes"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.